Merck announces FDA approval for GARDASIL against HPV-related anal cancer
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 ...
Read more on
订阅：
博文评论 (Atom)
没有评论:
发表评论